Skip to main content

Table 7 Univariate and multivariate Cox regression analysis for prognostic value of study variables to predict RFS in HER2-amplified breast cancer

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Characteristic Univariate analysis Multivariate analysis
n  p Mean RFS 95% CI for RFS p Exp (B) 95% CI for Exp (B)
Estrogen receptor status 177 0.090      
Progesterone receptor status 177 0.176      
Histological grade 174 0.831      
Ki-67 proliferation index 177 0.171      
Histological type (lobular/ductal) 168 0.774      
Lymph nodal status pN+ (vs pN0) 169 0.000*** 6.7 (8.4) 5.9 (8.0) – 7.5 (8.7) 0.002** 3.486 1.608, 7.555
Tumor size TNM stage ≥ pT3 (vs < pT3) 172 0.000*** 4.2 (7.9) 2.3 (7.5) – 6.2 (8.3) 0.001*** 4.016 1.703, 9.468
Patient age at diagnosis 177 0.118      
Menopausal status 176 0.082      
Cytokeratin 5/14 expression 167 0.447      
Basal phenotype (CK5/14+, ER-) 167 0.955      
Total cellular HER3 low (vs high) 177 0.004** 6.3 (8.0) 5.3 (7.6) – 7.3 (8.4) 0.020* 2.305 1.143, 4.648
Membranous HER3 low (vs high) 177 0.025* 6.6 (7.9) 5.6 (7.4) – 7.7 (8.3)    
Cytoplasmic HER3 low (vs high) 177 0.010* 5.9 (7.8) 4.2 (7.4) – 7.6 (8.2)    
NEDD4–1 expression 145 0.261      
NRDP1 nuclear expression 145 0.689      
NRDP1 cytoplasmic expression 145 0.711      
  1. Significant p-value (marked as *p<0.05, **p≤0.01, ***p≤0.001) means prognostic value of the variable to predict shorter RFS-time. Mean follow-up period for HER2+ BCA cohort was 5.3 years. Estimated mean RFS time is announced in years for each significant character